Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510897 · ClinicalTrials.gov registry record · Phase 3
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
A Phase 3 study, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,043
- Enrollment target
NCT03510897: Clinical Trial Phase 3 study, sponsored by Quark Pharmaceuticals.
NCT03510897 is a Phase 3 study that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 1,043 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03510897, a Phase 3 study, was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,043 participants
- Enrollment target
Study Summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Interventions
- DRUG Placebo
- DRUG teprasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2021-04-12 |
| Phase | Phase 3 |
Why NCT03510897 stopped before completion
NCT03510897 is an interventional study that assigns participants to a tested intervention. Its 1,043 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03510897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03510897 about?
NCT03510897 is a clinical study titled "QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery". This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
What is the current status of trial NCT03510897?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,043 participants. The study started on 2018-06-29. Estimated completion is 2021-04-12.
What interventions are being tested in trial NCT03510897?
The interventions under investigation include: Placebo (DRUG), teprasiran (DRUG).
Who is sponsoring clinical trial NCT03510897?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03510897's enrollment target sits among peer trials
1,043 284th of 2000 higher than 1,717 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI